Reply to comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?

Journal of the Formosan Medical Association

Volumn 113, Issue 1, 2014, Pages 63-64

  Yeh, Pei Ying ^a   Liao, Fang Ling ^a   Lin, Shuei Liong ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

BIOLOGICAL ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; DISEASE ASSOCIATION; ERYTHROPOIESIS; KIDNEY CELL; KIDNEY INJURY; KIDNEY TUBULE CELL; KNOCKOUT MOUSE; LETTER; NONHUMAN; RENAL PROTECTION; SIGNAL TRANSDUCTION; ANIMAL; HUMAN; KIDNEY; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; ERYTHROPOIETIN; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84892498404     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.05.005     Document Type: Letter

References (3)

1. Rafieian-Kopaei M., Nasri H. Comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?. J Formos Med Assoc 2013, 113:62.
2. Gouva C., Nikolopoulos P., Ioannidis J.P.A., Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004, 66:753-760.
3. Sinclair A.M., Coxon A., McCaffery I., Kaufman S., Paweletz K., Liu L., et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, 115:4264-4272.